PharmaceuticalCompaniesinGermany—MarketOverview

How large is Germany's pharmaceutical market?

Germany is Europe's largest pharmaceutical market with ~€62 billion in sales in 2024. Germany accounts for approximately 20% of total EU pharmaceutical market value. The statutory health insurance (GKV) system is the dominant payer. Germany is also the world's second-largest pharmaceutical exporter after the USA, with Bayer, Merck KGaA, and Boehringer Ingelheim as the leading global exporters.

What licences are needed to sell pharmaceuticals in Germany?

To sell pharmaceuticals in Germany: (1) Marketing authorisation (Zulassung) from BfArM (national) or EMA (EU centralised procedure) for the specific product. (2) Wholesale distribution licence (§52a AMG) from the Landesbehörde to distribute to pharmacies and hospitals. (3) Manufacturer licence (§13 AMG) if you produce in Germany. Retail sale to consumers: only through licensed Apotheken (pharmacies). Online sales of prescription drugs are prohibited; OTC online sales are allowed via EU-licensed online pharmacies.

What is AMNOG and how does it affect drug pricing in Germany?

AMNOG (Arzneimittelmarktneuordnungsgesetz, 2011) requires manufacturers to submit a benefit dossier (Nutzendossier) for new medicines to the G-BA within 3 months of market launch. G-BA assesses additional benefit vs. existing standard of care. Based on the assessment, manufacturers negotiate pricing with the GKV-Spitzenverband. If no agreement: arbitration or product withdrawal. This has significantly reduced launch prices for specialty drugs in Germany vs. pre-AMNOG levels.

Can a foreign company distribute pharmaceuticals in Germany?

Yes — with the required authorisations. A foreign company can: (1) Obtain a BfArM/EMA marketing authorisation for its product. (2) Establish a German GmbH distribution entity with a German wholesale licence (§52a AMG). (3) Alternatively, partner with an existing licensed German distributor (Großhändler) for distribution without establishing a local entity. German market access typically requires a local regulatory contact person (Pharmakovigilanzbeauftragter) registered with BfArM.

What are Germany's clinical trial regulations?

Clinical trials in Germany require: (1) BfArM authorisation for Phase I-III trials under the CTIVR (Clinical Trial Regulation EU 536/2014, fully applicable from 2022). (2) Ethics committee (Ethikkommission) approval — located at universities and medical chambers. (3) Registration in the EU clinical trials database (CTIS). Processing time: 30 days (combined BfArM + ethics review). Germany hosts the second-most clinical trials in the EU due to its university hospital infrastructure and research tradition.

What is the G-BA and what role does it play in German pharmaceutical pricing?

The Gemeinsamer Bundesausschuss (G-BA) is Germany's highest decision-making body in the statutory healthcare system. Under AMNOG, the G-BA assesses the additional benefit (Zusatznutzen) of new pharmaceuticals within 3 months of market launch. If the G-BA identifies additional benefit, the manufacturer negotiates the price with the GKV-Spitzenverband. If no benefit is found, the drug is reimbursed at the reference price (Festbetrag) of comparable treatments, often significantly below the manufacturer's desired price.

How does Germany's GKV (statutory health insurance) affect pharmaceutical sales?

The GKV (gesetzliche Krankenversicherung) covers approximately 90% of the German population and is the dominant payer for prescription medicines. GKV reimburses medicines according to the Arzneimittelformular (approved drug list), Festbeträge (reference prices), and AMNOG-negotiated prices. The GKV-Spitzenverband negotiates nationwide rebate contracts (Rabattverträge) directly with manufacturers, creating significant volume commitments in exchange for exclusive formulary inclusion. These rebate contracts are mandatory for GKV-reimbursed prescriptions.

What German regulations apply to medical devices (Medizinprodukte)?

Medical devices in Germany are regulated under EU MDR 2017/745 (Medical Device Regulation, fully applicable from May 2021) and EU IVDR 2017/746 (In Vitro Diagnostics Regulation). Germany is the EU's largest medical device market (~EUR 35 billion). The MPDG (Medizinprodukte-Durchführungsgesetz) implements EU regulations at the national level. Manufacturers must obtain CE marking via a Notified Body (Benannte Stelle) for most device classes. German Notified Bodies include TÜV Rheinland, TÜV SÜD, and Dekra.

What is the German Lieferkettengesetz (LkSG) and how does it affect pharma supply chains?

The Lieferkettensorgfaltspflichtengesetz (LkSG, Supply Chain Due Diligence Act), in force since January 2023, requires German companies with 1,000+ employees to conduct due diligence on their entire supply chain for human rights and environmental violations. For pharmaceutical companies, this means auditing active pharmaceutical ingredient (API) manufacturers in Asia (China, India) and other suppliers for labour standards. From 2024, the EU Corporate Sustainability Due Diligence Directive (CSDDD) will expand these requirements EU-wide.

How do biotech and pharmaceutical startups access funding in Germany?

Key funding sources for German pharma/biotech startups: (1) High-Tech Gründerfonds (HTGF) — seed funding of EUR 1–3M for university spinoffs. (2) BioRegio Programme — cluster-based funding from BMBF for life sciences. (3) KfW ERP-Innovationsprogramm — subsidised innovation loans. (4) Bayern Kapital (Bavaria) and NRW.BANK — state-level VC co-investment. (5) Horizon Europe — EU R&D grants (Germany is the second-largest recipient). (6) Private VC: Earlybird, Life Sciences Partners, Sofinnova. Germany's pharma clusters — Rhine-Main, Berlin-Brandenburg, Munich, Heidelberg — each have active investor ecosystems.